摘要
曲妥珠单抗联合帕妥珠单抗能够显著提高HER2阳性乳腺癌患者的无复发生存期(RFS)、总体生存期(OS)及病理完全缓解率(pCR),并且曲妥珠单抗联合帕妥珠单抗对HER2阳性乳腺癌具有良好的耐受性和有效性。本文总结曲妥珠单抗联合帕妥珠单抗对HER2阳性乳腺癌靶向治疗研究的相关文献并对此做一综述。
Trastuzumab combined with Pertuzumab could significantly improve the Relapse-Free Survival(RFS),Overall Survival(OS)and Pathological Complete Response rate(pCR)in patients with HER2-positive breast cancer,and Trastuzumab combined with Pertuzumab showed good tolerance and effectiveness for HER2-positive breast cancer.The literature on targeted therapy of HER2-positive breast cancer with Trastuzumab combined with Pertuzumab was summarized and reviewed.
作者
字春泽
杨鑫
谢增泽
叶钦
杨越
ZI Chunze;YANG Xin;XIE Zengze;YE Qin;YANG Yue(Department of Breast Surgery,Kunming First People’s Hospital,Kunming 650000, China)
出处
《中国老年保健医学》
2021年第3期110-112,共3页
Chinese Journal of Geriatric Care
基金
昆明市卫生科技人才培养暨“十百千”工程。
